Dr. Federico Collettini Awarded Prestigious Medical Research Award by Magle PharmaCept

15/09/2025

Magle PharmaCept, part of Magle Group, is proud to announce the awarding of its Mattias Lorenz Research Award to PD Dr. med. Federico Collettini, a distinguished radiologist at Charité Universitätsmedizin Berlin, Germany in recognition of their research project with Degradable Starch Microspheres Transarterial Chemoembolization (DSM-TACE) in metastatic melanoma patients with hepatic progression on immune checkpoint inhibitors.

The award is a part of Magle PharmaCept’s ongoing commitment to supporting medical professionals who are driving healthcare research and innovation to optimize patient care. Magle PharmaCept focuses on the sale and clinical activities of proprietary degradable starch microsphere (DSM) supports initiatives, encouraging scientific advancement and medical education across healthcare professionals, researchers, and patients.

“Dr. Collettini and team exemplifies the kind of visionary thinking that moves medicine forward,” said Justin Pierce, CEO at Magle PharmaCept. “This grant is not only a recognition of their contributions to demonstrate a novel approach combining DSM-TACE with immunotherapy, but also an investment in the future of patient care. We are proud to support their research, which holds promise to significantly impact treatment outcomes and has the potential to further personalize treatment strategies.”

The awarded research project, titled Initial experience with degradable starch microspheres transarterial chemoembolization in metastatic cutaneous melanoma patients with hepatic progression on immune checkpoint inhibitors. The project aimed to evaluate the safety and efficacy of DSM-TACE in metastatic melanoma patients with hepatic progression after an initial response to immune checkpoint inhibitors therapy (ICI). The authors concluded that integrating locoregional therapies such as DSM-TACE for patients with liver metastases from cutaneous melanoma receiving ICI treatment is feasible, safe, and effective in achieving local disease control, with the potential to prolong both progression-free and overall survival.

Dr. Collettini expressed gratitude for the recognition: “I’m honored to receive this support from Magle PharmaCept. The award will accelerate our efforts to bring more accurate, accessible, and effective therapies into clinical practice.”
With this initiative, Magle PharmCept continues to demonstrate its dedication to fostering scientific excellence and supporting frontline medical innovation. The company believes that collaboration with academia is essential to overcoming today’s healthcare challenges and improving outcomes for patients around the world.